Please login to the form below

Not currently logged in
Email:
Password:

Celltrion Healthcare

This page shows the latest Celltrion Healthcare news and features for those working in and with pharma, biotech and healthcare.

Celltrion’s investigational mAb cuts COVID-19 recovery time

Celltrion’s investigational mAb cuts COVID-19 recovery time

South Korean-based Celltrion has posted positive data for its investigational COVID-19 targeting monoclonal antibody (mAb) from a phase 2/3 study. . ... especially in moderate patients aged 50 years and over,” said HoUng Kim head of medical and

Latest news

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    Mundipharma has strengthened its partnership with biopharmaceutical group Celltrion Healthcare by securing rights to its trastuzumab biosimilar. ... Commenting on the partnership, Man Hoon Kim, president and CEO of Celltrion Healthcare, said: “We are

  • Standing out in a crowd Standing out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars. ... PME sat down recently to discuss pricing, market access and regulatory challenges with Ho-Ung Kim, division head of

  • Mundipharma to launch first MabThera biosimilar in EU Mundipharma to launch first MabThera biosimilar in EU

    approval. Developed by South Korean biosimilar specialist Celltrion Healthcare, Truxima is set to be launched in the UK, Germany, Italy, the Netherlands, Belgium, Ireland and Luxembourg by UK-based pharma network

  • Patients 'sceptical' about biosimilars, says EULAR Patients 'sceptical' about biosimilars, says EULAR

    A cost-effective treatment option like biosimilar infliximab will help to decrease the current and extensive burden on healthcare systems across Europe," commented Celltrion chief executive Stanley Hong. ... as $50bn in savings to healthcare systems

  • First mAb biosimilars set for European approval First mAb biosimilars set for European approval

    Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP. ... infliximab) filed by Celltrion Healthcare and Hospira.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...